Chronic Rhinosinusitis Treatment Guidelines

Introduction to Antibiotic Use

The American Academy of Otolaryngology guidelines recommend amoxicillin-clavulanate as first choice for acute bacterial exacerbations requiring antibiotics, with a higher efficacy tier of 90-92% 1
The European Position Paper on Rhinosinusitis and Nasal Polyps (2020) does not support routine use of azithromycin for chronic rhinosinusitis, noting inconsistent results across studies 2

Azithromycin shows significantly lower predicted clinical efficacy (77-81%) compared to respiratory quinolones, ceftriaxone, and amoxicillin/clavulanate (90-92%) for rhinosinusitis 1
Respiratory fluoroquinolones are recommended as an alternative for adults with moderate-severe disease or penicillin allergy 1

Azithromycin is effective against a wide range of gram-positive, gram-negative, and atypical pathogens, including Haemophilus influenzae, Moraxella catarrhalis, and atypical organisms like Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella species, with increasing resistance rates varying from <10% to >90% globally 3
Azithromycin has better gram-negative coverage than erythromycin, and is more active against H. influenzae than other macrolides, although many Enterobacteriaceae, Pseudomonas, and Acinetobacter species have reduced permeability to macrolides 3
Azithromycin is indicated for respiratory tract infections, particularly community-acquired pneumonia caused by susceptible S. pneumoniae, H. influenzae, M. pneumoniae, and C. pneumoniae, according to the Infectious Diseases Society of America 4

Resistance rates are increasing globally, particularly for S. pneumoniae, with extensive macrolide use providing strong selective pressure for resistance development 3
Azithromycin's long half-life creates prolonged periods of subinhibitory concentrations, potentially promoting resistance, and alternative agents may be preferred in areas with high pneumococcal resistance 3
Azithromycin monotherapy is contraindicated in patients with non-tuberculous mycobacterial infections due to the risk of developing resistance, according to the American Thoracic Society 3
The Infectious Diseases Society of America recommends that azithromycin should not be used for severe streptococcal infections due to its bacteriostatic nature and increasing resistance patterns 5

The American College of Physicians recommends penicillin as the first-line therapy for streptococcal infections, with azithromycin as an alternative for penicillin-allergic patients, at a dosing of 12 mg/kg once daily (maximum 500 mg) for 5 days 6
The Infectious Diseases Society of America suggests that for necrotizing infections involving streptococci, combination therapy with clindamycin and penicillin is preferred over azithromycin 5
For streptococcal pharyngitis, studies show higher recurrence rates with azithromycin compared to penicillin, as noted by the American College of Physicians 5
Azithromycin may be considered for penicillin-allergic patients who cannot tolerate respiratory fluoroquinolones, refractory cases failing first-line antibiotics and intranasal corticosteroids 1